Moderna announced positive clinical trial data on three experimental vaccines and said it will move those shots to final stage studies.
The update brings the biotech company a step closer to having multiple products on the market, which it badly needs amid plunging demand for Covid shots worldwide.
Moderna will chart its post-Covid future Wednesday during its fifth annual “Vaccines Day,” an investor event in Boston.

Those vaccines include a shot against norovirus, a highly contagious stomach bug that causes vomiting and diarrhea; a vaccine against Epstein-Barr virus, a common herpes virus that can cause contagious infections and is associated with some cancers; and a shot designed to target a virus that causes shingles and chickenpox.